A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma

NCT06650514 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
10
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Vall d'Hebron Institute of Oncology

Collaborators